Skip to content

Lantheus announces FDA approval of BRAVNETSA™ (Lutetium Lu 177 Dotatate). Learn more.

Because we’re making headlines

Please visit our investor site for a complete list of recent and archived press releases, follow us on LinkedIn for social media updates and browse below for additional media resources.

Latest press releases

See all press releases

Press release

September 30, 2026

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Read more

Press release

September 28, 2026

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Read more

Press release

September 22, 2026

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

Read more

Additional resources

Media library

Images, videos and other assets bring news about Lantheus to life.

Events

Events allow us to connect with our people, patients and partners.

Investors

All investor resources can be found on our dedicated investor website.

Contact

Media

Melissa Downs
Executive Director
External Communications

646-975-2533

media@lantheus.com

Investors

Mark Kinarney
Vice President
Investor Relations

978-671-8842

ir@lantheus.com